The Incidence of SARS-COV-2 Manifestations in the Central Nervous System: A Rapid Review and Meta-Analysis

Verena Mayr (verena.mayr@donau-uni.ac.at)  
Danube Private University  https://orcid.org/0000-0002-8265-554X

Glechner Anna  
Donau-Universitat Krems Fakultat fur Gesundheit und Medizin

Gerald Gartlehner  
Donau-Universitat Krems Fakultat fur Gesundheit und Medizin

Irma Klerings  
Donau-Universitat Krems Fakultat fur Gesundheit und Medizin

Peter Lackner  
Wiener Krankenanstaltenverbund

Research article

Keywords: COVID-19, SARS-CoV-2, cerebrovascular diseases and cerebral circulation, stroke, viral infections, review, meta-analysis

DOI: https://doi.org/10.21203/rs.3.rs-44795/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 and presents itself mainly as a respiratory tract infection. However, reports of associated central nervous system (CNS) manifestations are increasing.

Methods: We conducted this rapid review to determine the frequency of CNS manifestations of COVID-19 (CNS symptoms, acute cerebrovascular disease, and infectious/inflammatory CNS diseases) and to summarize the current evidence for direct invasion of the CNS by SARS-CoV-2. An information specialist searched Ovid MEDLINE, the CDC: COVID-19 Research Articles Downloadable and WHO COVID-19 Databases, CENTRAL, and Epistemonikos.org on May 13, 2020. Two reviewers screened abstracts and potentially relevant full-text publications independently. The data extraction, assessment of risk of bias, and certainty of evidence using GRADE was done by one reviewer and double-checked by another. If possible and reasonable, a meta-analysis was carried out.

Results: We identified 13 relevant studies (four cohort studies, nine case studies) with a total of 866 COVID-19 patients. In a Chinese cohort, dizziness (16.8%; 36 of 214) and headache (13.1%; 28 of 214) were the most common CNS symptoms reported. A meta-analysis of four cohort studies including 851 COVID-19 patients showed an incidence of 3.3% (95% CI: 2.2–4.9) for ischemic stroke (follow-up: one to five weeks). In 13 of 15 encephalitis case studies, PCR testing of the cerebrospinal fluid did not detect any virus components.

Conclusion: CNS manifestations occur frequently in patients with COVID-19. It is important to integrate neurologists into the multiprofessional COVID-19 treatment team to detect neurological complications early and to treat them correctly.

1. Background

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the Severe Acute Respiratory Syndrome - Coronavirus 2 (SARS-CoV-2) [1]. The time between the first case of illness (December 31, 2019, Hubei Province, China) and the declaration of a pandemic by the World Health Organization (WHO, March 11, 2020) was rather short [2]. Clinically, COVID-19 presents itself mainly as a respiratory tract infection with fever, fatigue, and dry cough and with infiltrates on chest X-ray [3]. Pneumonia and the subsequent development of acute respiratory distress syndrome are the most common severe manifestations of the disease [3]. As the number of infected people increased, more differentiated data on the symptoms emerged. More and more studies have been published on neurological manifestations such as the loss of the sense of smell and taste and also on serious complications such as encephalitis or stroke [4–6]. A yet unanswered question is whether the virus has a direct effect on the central nervous system (CNS), or whether these neurological manifestations should be considered parainfectious. The neuroinvasive potential of SARS-CoV-2 is still under debate. Proposed mechanisms for CNS invasion are hematogenous spread via an impaired blood–brain barrier, neuronal retrograde, or transcribable routes [7, 8].

Neurological damage to the CNS was observed in earlier epidemics of diseases such as Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS), which were also triggered by coronaviruses [9, 10]. In SARS, the pathogen could be detected by a polymerase chain reaction (PCR) in the
cerebrospinal fluid (CSF) and brain tissue [11–15]. To determine the frequency of CNS complications and to investigate whether the virus infection affects the brain tissue directly, we conducted a rapid review. As manifestations of the CNS underlie different pathomechanisms, we phrased the following key questions (KQs) as:

**KQ1**
What is the incidence of central nervous symptoms in patients infected with SARS-CoV-2?

**KQ2**
What is the incidence of acute cerebrovascular disease in patients infected with SARS-CoV-2?

**KQ3**
Does SARS-CoV-2 cause infectious/inflammatory diseases of the CNS?

**KQ3.1**
Does the virus enter the CNS or should neurological manifestations be considered parainfectious?

### 2. Methods

We adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) throughout this manuscript [16].

Compared with the methods of a systematic review, the review team applied the following methodological shortcuts for this rapid review:

- no searches of grey literature;
- no dual independent data extraction;
- no dual independent risk of bias assessment and rating of the certainty of evidence.

#### 2.1 Literature search

An experienced information specialist conducted a systematic search of the literature published from January 1, 2019 to April 15, 2020 in Ovid MEDLINE, the CDC: COVID-19 Research Articles Downloadable Database, the WHO COVID-19 Database, CENTRAL (Cochrane Library/Wiley), and Epistemonikos.org. On May 13, 2020, the information specialist performed an updated search. The search strategies were modified based on the findings of the initial searches, and the results were deduplicated with those of the first search. We also conducted similar article searches in PubMed based on the first 100 linked references for each seed article. Seed articles were potentially eligible studies identified during the preliminary searches or in the first round of databases searches. The additional file provides the detailed search strategies [see Additional file 1]. Furthermore, the review authors screened the reference lists of the included studies to identify relevant citations that were not detected by searches of electronic databases.
2.2 Eligibility criteria

We included studies concerning central nervous symptoms (e.g., dizziness, headache, etc.), encephalopathy, acute cerebrovascular disease, and infectious (e.g., encephalitis, meningitis) or inflammatory CNS diseases in confirmed COVID-19 patients older than 18 years. Studies with suspected but not confirmed cases of COVID-19 and including children and patients with primary neurological diseases or taking additional immunosuppressive drugs (e.g., for multiple sclerosis) were excluded. Only articles in English and German were considered. After a quick presearch, we prespecified a best-evidence approach for the literature screening. For KQ1 and KQ2, case studies were excluded because observational studies were already available. Due to the lack of data on infectious/inflammatory CNS disorders in COVID-19 cases, there were no restrictions regarding the specific study design for KQ3 and KQ3.1. However, case reports without SARS-CoV-2 PCR testing of the CSF were excluded.

2.3 Screening process

Two researchers independently screened all titles and abstracts of both searches based on the predefined inclusion and exclusion criteria. Included abstracts were retrieved as full-text publications and independently screened by two reviewers. In cases of disagreements about eligibility, the two reviewers reached consensus by discussion. The team screened the literature using Covidence Systematic Review software (www.covidence.org).

2.4 Quality assessment

The review team assessed the risk of bias of the observational studies using an adapted version of the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool [17]. A single reviewer rated the risk of bias for each relevant outcome of each study; a second reviewer checked the ratings. As there is no validated risk of bias checklist for case studies available, the review team checked whether SARS-CoV-2 PCR tests were carried out twice to reduce the risk of a false positive result.

To assess the certainty of the body of evidence for all the outcomes of interest, we applied the approach by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group [18]. A single review author applied GRADE, and a second review author verified all judgments. GRADE uses four categories to classify the certainty of evidence. A high certainty of evidence means that we were very confident the estimated effect lies close to the true effect; a moderate certainty assumes it is likely to be close; with a low certainty rating, the true effect might substantially differ from the true effect; and a very low certainty means that we had no confidence in the effect estimate.

2.5 Data extraction

One reviewer extracted data from the included studies into standardized tables; a second reviewer checked the data extraction for completeness and correctness. We extracted the following data: report characteristics (year, authors), study design, setting, participant characteristics (age, preexisting medical conditions, main symptoms,) and results.

2.6 Synthesis
We synthesized the results both narratively and in tabular form. If three or more studies were similar with respect to outcomes and populations and provided data for quantitative analyses, we conducted meta-analyses. Therefore, we conducted a test of heterogeneity ($I^2$ statistic, Cochran’s q-test) and applied the DerSimonian and Laird method for random-effects models. A sensitivity analysis was performed by excluding high risk of bias studies. We planned to assess publication bias using funnel plots, Egger's regression intercept, and Kendall’s S statistic. All statistical analyses were conducted using Comprehensive Meta-Analysis (CMA), version 2.2.050 (www.meta-analysis.com).

3. Results

The PRISMA flow diagram in Fig. 1 provides an overview of the study selection process. Our searches identified 13 relevant studies published in 15 articles [6, 19–31]. Of these, four were cohort studies, two case series, and seven case reports.

The cohort studies were retrospective observational studies and were performed in France [19], Italy [21], the Netherlands [20], and Wuhan, China [6, 22]. All four retrospective observational studies including 851 individuals described acute cerebrovascular disease related to COVID-19 [6, 19–22]. Two retrospective observational studies including 279 COVID-19 patients described central nervous symptoms relating to COVID-19 [6, 19, 22]. One of the four studies presented the data of 221 hospitalized COVID-19 patients admitted to hospital in Wuhan [6, 22]. The data of these 221 patients were analyzed at two different time-points: the first publication presented the data of 214 patients and focused on neurological symptoms [22]. In the preprint of the second analysis, seven patients were added, the observation period was extended by ten days, and additional data concerning cerebrovascular disease was released [6]. One French study was published in a “Letter to the Editor” and provided only limited data[19]. The baseline characteristics of the observational studies and the case studies are shown in Tables 1 and 2, respectively.
### Table 1
Characteristics, main results, and risk of bias of the observational studies

| Study design                                      | Lodigiani 2020\(^{21}\) | Mao L 2020\(^{22}\) | Klok 2020\(^{20}\) | Helms J 2020\(^{19}\) |
|--------------------------------------------------|---------------------------|---------------------|-----------------|---------------------|
| Study design                                     | KQ2                       | KQ1, KQ2            | KQ2             | KQ1, KQ2            |
| Number of patients (severe cases)                | N = 388 (61)              | N = 221 (94)        | N = 184 (184)   | N = 58 (58)         |
| Setting                                          | University hospital in Milan (Italy), admission: February 13 to April 4, 2020 | Union Hospital, Wuhan (China), admission: January 16 to February 29, 2020 | Dutch ICUs, admission: March 7 to April 5, 2020 | ICUs in Strasbourg (France), admission: March 3 to April 3, 2020 |
| Mean age (years; SD)                             | 66 (55–75)\(^1\)         | 53.3 (± 15.9)       | 64 (± 12)       | 63\(^1\)           |
| Sex (female n, %)                                | 124 (32%)                 | 90 (40.7%)          | 45 (24.5%)      | NA                  |
| Medical history (n, %)                           |                           |                     |                 |                     |
| Hypertension                                     | 183 (47.2%)               | 31 (14%)            | NA              | NA                  |
| Diabetes                                         | 88 (22.7%)                | 31 (14%)            | NA              | NA                  |
| Cardio-cerebrovascular disease                   | 74 (19.1%)\(^2\)         | 17 (7.7)            | NA              | NA                  |
| Neurologic disorders                             | NA                        | NA                  | NA              | 7 (12.1%)           |
| Malignancy                                       | 25 (6.4%)                 | 14 (6.3%)           | 5 (2.7%)\(^3\) | NA                  |

\(^1\) median age: years, quartile 1 – quartile 3; \(^2\) prior stroke n = 20 of 388, coronary artery disease n = 54 of 388; \(^3\) active cancer

Abbreviations: ICU: intensive care unit; KQ: key question; NA: not available; SD: standard deviation
| Study characteristics | Setting | Patient characteristics | Main symptoms | Test results |
|-----------------------|---------|-------------------------|---------------|-------------|
| Bernard-Valnet et al. 2020<sup>23</sup> case series (N = 2) KQ3, KQ3.1 | Central University Hospital Vaudois (Switzerland) 2020 | case 1: 64-year-old female medical history: no psychiatric diseases, other NA | general symptoms: mild asthenia, myalgia, cough neurological symptoms: psychotic symptoms, disorientated, tonic–clonic seizures | case 1: MRI: unremarkable CSF: exclusion of neurotropic viruses, antineuronal antibodies negative EEG: nonconvulsive focal status epilepticus (at admission) SARS-CoV-2 PCR Test: nasopharyngeal 1x positive, CSF 1x negative |
|                       |         | case 2: 67-year-old female medical history: NA | neurological examination: no neck stiffness or focal signs, bilateral grasping, attention deficit, verbal and motor perseverations | case 2: MRI: unremarkable CSF EEG: NA SARS-CoV-2 PCR Test: nasopharyngeal 1x positive, CSF 1x negative |

Abbreviations: ARDS: acute respiratory distress syndrome; CNS: central nervous system; COVID-19: coronavirus disease 2019; CSF: cerebrospinal fluid; CT: computer tomography; EEG: electroencephalography; GCS: glascow coma scale; HSV: herpes simplex virus; ICU: intensive care unit; KQ: key question; MRI: magnetic resonance imaging; NA: not available; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome - coronavirus 2; VZV: varicella-zoster virus
| Study characteristics | Setting | Patient characteristics | Main symptoms | Test results |
|-----------------------|---------|-------------------------|---------------|-------------|
| Chaumont et al. 2020²⁴ case study | University Hospital Guadeloupe (French Indies) | 69-year-old male | **general symptoms:** headache, fever, myalgia cough, dyspnea, diarrhea | MRI: unremarkable |
| KQ3, KQ3.1 | 2020 | medical history: none | **neurological symptoms:** anosmia, ageusia, painful neck, confusion, walking disability | CSF: purely lymphocytic (37 × 10⁶/L), no red blood cells, increased protein 84 mg/dL, normal glucose level, exclusion of HSV, VZV, enterovirus |
|  |  |  | mechanical ventilation: no | EEG: bilateral slowed activity without seizures |
|  |  |  | neurological examination: altered consciousness (GCS of 14 at admission), neck stiffness, right-sided hemiparesis, swallowing disorders | SARS-CoV-2 PCR Test: nasopharyngeal 2x |
|  |  |  |  | negative, CSF 2x negative, bronchoalveolar lavage 1x positive |

Abbreviations: ARDS: acute respiratory distress syndrome; CNS: central nervous system; COVID-19: coronavirus disease 2019; CSF: cerebrospinal fluid; CT: computer tomography; EEG: electroencephalography; GCS: glasgow coma scale; HSV: herpes simplex virus; ICU: intensive care unit; KQ: key question; MRI: magnetic resonance imaging; NA: not available; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome - coronavirus 2; VZV: varicella-zoster virus
| Study characteristics | Setting | Patient characteristics | Main symptoms | Test results |
|-----------------------|---------|-------------------------|---------------|--------------|
| Dogan et al. 202025 | ICU at Altunizade Acibadem Hospital, (Istanbul, Turkey) | mean age (y): 49.2 (± 13.9) | symptoms: NA | MRI: 3x compatible with meningoencephalitis, 3x unremarkable |
| case series (N = 6)  | March–April 2020 | sex (n, %): 1 female (16.7%) | supplement of setting: 29 COVID-19 patients developed severe ARDS, admitted to the ICU and either failed to regain consciousness after mechanical ventilation or developed agitated delirium. In 6 of these patients, CNS involvement was diagnosed. | CSF: high CSF protein levels without pleocytosis in all cases, exclusion of neurotropic viruses NA |
| KQ3, KQ3.1           |         | medical history (n, %): none:1 (16.7%) | | EEG: NA |
|                      |         | hypertension: 4 (66.7%) | | SARS-CoV-2 PCR Test: nasopharyngeal 1x positive, CSF 1x negative |
|                      |         | diabetes: 2 (33.4%) | | |
|                      |         | obesity: 1 (16.7%) | | |

Abbreviations: ARDS: acute respiratory distress syndrome; CNS: central nervous system; COVID-19: coronavirus disease 2019; CSF: cerebrospinal fluid; CT: computer tomography; EEG: electroencephalography; GCS: glasgow coma scale; HSV: herpes simplex virus; ICU: intensive care unit; KQ: key question; MRI: magnetic resonance imaging; NA: not available; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome - coronavirus 2; VZV: varicella-zoster virus
| Study characteristics | Setting | Patient characteristics | Main symptoms | Test results |
|-----------------------|---------|-------------------------|---------------|-------------|
| Hanna Huang et al. 2020<sup>27</sup> | Hospital Downtown Los Angeles (USA) | 41-year-old female medical history: obesity, diabetes | **general symptoms:** headache, fever **neurological symptoms:** new-onset seizure mechanical ventilation: no neurological examination: neck stiffness, photophobia, no focal signs, in the course of the disease: disorientation, hallucinations | MRI: NA CSF: 70 white cells with 100% lymphocyte. Red cells 65, protein 100, glucose 120 (serum glucose 200), exclusion of HSV EEG: generalized slowing with no epileptic discharges SARS-CoV-2 PCR Test: nasopharyngeal 1x positive, CSF 1x positive |
| Duong et al. 2020<sup>26</sup> case study | April 2020 | | | |

KQ3, KQ3.1

**Abbreviations:** ARDS: acute respiratory distress syndrome; CNS: central nervous system; COVID-19: coronavirus disease 2019; CSF: cerebrospinal fluid; CT: computer tomography; EEG: electroencephalography; GCS: glasgow coma scale; HSV: herpes simplex virus; ICU: intensive care unit; KQ: key question; MRI: magnetic resonance imaging; NA: not available; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome - coronavirus 2; VZV: varicella-zoster virus
| Study characteristics | Setting | Patient characteristics | Main symptoms | Test results |
|------------------------|---------|-------------------------|---------------|-------------|
| Moriguchi et al. 2020<sup>28</sup> | ICU of the University Hospital of Yamanashi (Japan) | 24-year-old male | general symptoms: headache, fever, sore throat | MRI: right lateral ventriculitis and encephalitis mainly on right mesial lobe and hippocampus |
| case study KQ3, KQ3.1 | March 2020 | medical history: NA | neurological symptoms: consciousness impairment, generalized seizures, | CSF: clear, colorless, initial pressure higher than 320 mm H<sub>2</sub>O, cell count 12/µl, 10 mononuclear and 2 polymorph nuclear cells, no red blood cells, exclusion of HSV-1, VZV; |
| Pilotto et al. 2020<sup>29</sup> | Brescia Hospital (Italy) | 60-year-old male | general symptoms: fever, cough | EEG: NA |
| case study KQ3, KQ3.1 | April 2020 | medical history: none | neurological symptoms: consciousness impairment, irritability, confusion, cognitive fluctuations, asthenia | SARS-CoV-2 PCR Test: nasopharyngeal 2x negative, CSF 2x positive |
| | | | mechanical ventilation: no | MRI: unremarkable |
| | | | neurological examination: severe akinetic syndrome associated to mutism, positive palomental and glabella reflexes, moderate nuchal rigidity, no focal signs | CT: unremarkable |
| | | | SARS-CoV-2 PCR Test: nasopharyngeal 1x positive, CSF 1x negative | CSF: mild lymphocytic pleocytosis (18 µ/L), moderate increase of protein (69.6 mg/dL), exclusion of neurotropic viruses |

Abbreviations: ARDS: acute respiratory distress syndrome; CNS: central nervous system; COVID-19: coronavirus disease 2019; CSF: cerebrospinal fluid; CT: computer tomography; EEG: electroencephalography; GCS: glascow coma scale; HSV: herpes simplex virus; ICU: intensive care unit; KQ: key question; MRI: magnetic resonance imaging; NA: not available; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome - coronavirus 2; VZV: varicella-zoster virus
| Study characteristics | Setting | Patient characteristics | Main symptoms | Test results |
|-----------------------|---------|-------------------------|---------------|-------------|
| Ye et al. 2020<sup>30</sup> case study | Wuhan Huoshenshan Hospital, (China) | male, age NA medical history: NA | **general symptoms:** fever, dyspnea, myalgia | MRI: NA CT: unremarkable CSF: pressure 220 mmHg, white blood cells, protein and glucose within normal limits, exclusion of neurotropic viruses NA |
| KQ3, KQ3.1 | February 2020 |  | **neurological symptoms:** confusion, consciousness impairment | neurological examination: meningeal irritation signs and extensor plantar response positive | EEG: NA SARS-CoV-2 PCR Test: nasopharyngeal 1x positive, CSF 1x negative |
| Yin et al. 2020<sup>31</sup> case study | Wuhan (China) | 64-year-old male medical history: no hypertension, no diabetes, no cardio-cerebrovascular disease | **general symptoms:** fever, cough | MRI: NA CT: unremarkable CSF: colorless, clear, pressure 200 mmHg, cell count: $1 \times 10^6$/L; protein 275.5 mg/L, glucose 3.14 mmol/L, exclusion of neurotropic viruses NA EEG: NA SARS-CoV-2 PCR Test: nasopharyngeal repeatedly positive, CSF 1x negative |
| KQ3, KQ3.1 | February 2020 |  | **neurological symptoms:** insomnia, muscle soreness, lethargy | neurological examination: consciousness impairment, lower limbs: positive ankle clonus (left pronounced), left positive Babinski and Chaddock signs, slight neck stiffness, positive Brudzinski sign, positive leg raise test |

Abbreviations: ARDS: acute respiratory distress syndrome; CNS: central nervous system; COVID-19: coronavirus disease 2019; CSF: cerebrospinal fluid; CT: computer tomography; EEG: electroencephalography; GCS: glasgow coma scale; HSV: herpes simplex virus; ICU: intensive care unit; KQ: key question; MRI: magnetic resonance imaging; NA: not available; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome - coronavirus 2; VZV: varicella-zoster virus
| Study characteristics | Setting | Patient characteristics | Main symptoms | Test results |
|-----------------------|---------|-------------------------|---------------|-------------|
| Zanin et al. 2020<sup>33</sup> | Brescia Hospital (Italy) | 54-year-old women | general symptoms: none | **MRI**: alterations of the periventricular white matter, hyperintense in T2WI, without restriction of diffusion or contrast enhancement, Similar lesions at the bulbo–medullary junction and in the cervical and dorsal spinal cord |
| case study KQ3, KQ3.1 | 2020 | medical history: anterior communicating artery aneurysm treated surgically; other diseases NA | neurological symptoms: anosmia, ageusia, new-onset seizure | **CT**: unremarkable |
| | | | mechanical ventilation: yes | **CSF**: Chemical–physical examination was normal, no signs of multiple sclerosis, exclusion of neurotropic viruses |
| | | | neurological examination: GCS of 12 without focal sensorimotor deficits; families reported no signs of both tongue biting and incontinence. | **EEG**: two seizures starting from right frontotemporal region and diffusing in homologous contralateral hemisphere |
| | | | | **SARS-CoV-2 PCR Test**: nasopharyngeal repeatedly positive, CSF 1x negative |

Abbreviations: ARDS: acute respiratory distress syndrome; CNS: central nervous system; COVID-19: coronavirus disease 2019; CSF: cerebrospinal fluid; CT: computer tomography; EEG: electroencephalography; GCS: glasgow coma scale; HSV: herpes simplex virus; ICU: intensive care unit; KQ: key question; MRI: magnetic resonance imaging; NA: not available; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome - coronavirus 2; VZV: varicella-zoster virus

Two studies from China and Italy were classified as low risk of bias [6, 21, 22], while two studies from the Netherlands and France were rated as high risk of bias due to the insufficient description of relevant confounders [19, 20].

### 3.1 KQ1: Central nervous symptoms related to SARS-CoV-2
Two retrospective observational studies including 279 COVID-19 patients described central nervous symptoms relating to COVID-19 [6, 19, 32]. Both had a different focus: The retrospective study from Wuhan covered general neurological manifestations in the context of COVID-19 diseases and included 41.1% (88 of 214) [32] of cases with severe illness [32]. The French study by Helms et al. focused on unexplained encephalopathic symptoms in COVID-19 patients in intensive care units (ICUs) [19]. The age ranged from a mean age of 53 years in the Chinese study to a median age of 58 years in the French study.

In the Wuhan study, neurological signs and symptoms were observed in 36.4% (78 of 214) of patients during COVID-19 disease, and about 24.8% (53 of 214) had symptoms affecting the CNS [6]. Categories within the CNS-related symptoms were dizziness (16.8%; 36 of 214), headache (13.1%; 28 of 214), consciousness impairment (7.5%; 16 of 214), ataxia (0.5%; 1 of 214), and seizures (0.5%; 1 of 214). These CNS symptoms were more common in the severely ill group (30.7%; 27 of 88) than in the non-seriously ill group (20.6%: 26 of 126 people); in particular, this was the case for impairment of consciousness (14.8% vs. 2.4%, p < 0.001). This category also differed from the others with respect to the time of onset: while the other CNS symptoms manifested early during the first two days of hospitalization, impairment of consciousness occurred on average after eight and nine days, respectively.

The study performed in France presented the data of 58 COVID-19 patients with acute respiratory distress syndrome (ARDS) [19]. However, the brevity of the publication allowed only a limited data collection. Overall, 22.4% (13 of 58) showed encephalopathy features that could not be otherwise explained, for example, by side effects of drug treatment. In addition, 67.2% (39 of 58) showed positive pyramidal trajectory signs, and of the 45 patients discharged at the time of publication, 33.3% (15 of 45) had dysexecutive syndrome.

Table 3 provides the main results, risk of bias, and certainty of evidence rating for central nervous symptoms relating to COVID-19.
### Table 3
Central nervous symptoms relating to COVID-19

| Author, Year       | Study design                   | Risk of bias | Population              | Follow-up          | Outcome                          | Incidence     | Certainty of evidence |
|--------------------|--------------------------------|--------------|-------------------------|--------------------|----------------------------------|---------------|------------------------|
| Helms et al. 2020  | Retrospective observational study | high         | Intensive Care Unit     | NA                 | Unexplained encephalopathy features | 22.4% (13 of 58) | ⊕ΟΟΟ VERY LOW¹,²      |
| Mao et al. 2020    | Retrospective observational study | low          | Severe disease: 41.1% (88 of 214) | Up to 5 weeks      | Any central nervous symptom       | 24.8% (53 of 214) | ⊕ΟΟΟ VERY LOW¹,²      |

- Dizziness 16.8% (36 of 214)
- Headache 13.1% (28 of 214)
- Consciousness impairment 7.5% (16 of 214)
- Ataxia 0.5% (1 of 214)
- Seizures 0.5% (1 of 214)

¹ retrospective study design, ² imprecision

### 3.2 KQ2: Acute cerebrovascular disease related to SARS-CoV-2

Four retrospective observational studies including 851 individuals reported on the incidence of acute cerebrovascular disease relating to COVID-19 [6, 19–22]. While three studies referred only to ischemic strokes [19–21], the Chinese study also included other acute cerebrovascular manifestations (cerebral hemorrhage, cerebral venous sinus thrombosis) [6, 22]. The largest study from Italy contained only 15.7% severe cases of COVID-19 (61 of 388) [21]; the other three studies included 42.5% (94 of 221) of severe cases [6, 22] or only considered patients with admission to an ICU for inclusion [19, 20].

The Wuhan study was the only one of the included publications that provided the data of the total population and of the patients with an acute cerebrovascular event separately. Patients with an acute cerebrovascular event were significantly older (71.6 years [± 15.7] vs. 52.1 years [± 15.3], p < 0.05) and had an increased incidence of severe COVID-19 disease (84.6% vs. 39.9%, p < 0.01) [6]. COVID-19 patients with an acute cerebrovascular event had more preexisting conditions than those without an acute cerebrovascular event, in particular, arterial hypertension (69.2% vs. 22.1%, p < 0.001), diabetes (46.2% vs. 12%, p = 0.004), and cardio-cerebrovascular disease (23.1% vs. 6.7%, p = 0.07).

Table 4 provides the main results, risk of bias, and certainty of evidence rating for acute cerebrovascular events relating to SARS-CoV-2.
### Table 4

**Acute cerebrovascular diseases relating to COVID-19**

| Outcome                        | Author, Year       | Number of studies | Study design     | Risk of bias | Population | Follow-up | Event-Rate | Certainty of evidence |
|-------------------------------|--------------------|-------------------|------------------|--------------|------------|-----------|------------|----------------------|
| Acute ischemic stroke         | Lodigiani et al. 2020<sup>21</sup> | 2                 | Retrospective study | low          | Severe disease: 15.7% (61 of 388) | Median 10 days | 2.3% (9 of 388) | ⊕⊕OO LOW<sup>1</sup> |
|                               | Li et al. 2020<sup>6</sup> |                   |                  |              | Severe disease: 42.5% (94 of 221) | Up to 5 weeks | 5.0% (11 of 221) |           |
|                               | Klok et al. 2020<sup>20</sup> | 2                 | Retrospective study | high         | Severe disease: 100% (184 of 184) | Median 14 days | 2.7% (5 of 184) |           |
|                               | Helms et al. 2020  |                   |                  |              | Severe disease 100% (58 of 58)   | NA         | 3.4% (2 of 58)  |           |
| Cerebral venous sinus thrombosis | Li et al. 2020<sup>6</sup> | 1                 | Retrospective study | low          | Severe disease 42.5% (94 of 221) | Up to 5 weeks | 0.5% (1 of 221) | ⊕OOO VERY LOW<sup>1,2</sup> |
| Cerebral hemorrhage           | Li et al. 2020<sup>6</sup> | 1                 | Retrospective study | low          | Severe disease 42.5% (94 of 221) | Up to 5 weeks | 0.5% (1 of 221) | ⊕OOO VERY LOW<sup>1,2</sup> |

<sup>1</sup> retrospective study design, <sup>2</sup> optimal information size not met

#### 3.2.1. Ischemic strokes relating to SARS-CoV-2

We performed a meta-analysis of four observational studies that included the data of 851 patients with COVID-19 to assess the incidence of ischemic strokes (Fig. 2). The overall incidence of ischemic strokes in COVID-19 patients was 3.3% (95% CI: 2.2–4.9; follow-up range one to five weeks after hospital admission). A sensitivity analysis was conducted by excluding high risk of bias studies and showed no major changes in the incidence of ischemic strokes (3.4%; 95% CI: 1.16–7.2; follow-up range one to five weeks after hospital admission). However, it should be noted that the sensitivity analyses resulted in the loss of half the studies. Due to the small number of studies, an assessment of publication bias was not carried out.

Among the studies with a low risk of bias, in the study population with more severe cases of COVID-19, a higher patient proportion suffered an ischemic stroke than in the study population with less severe cases (5.0% vs. 2.3%) [6, 21].

The Italian study reported that in six of nine cases, ischemic stroke was the primary reason for admission to the hospital. The Wuhan study measured a different period: the mean time from the onset of COVID-19 symptoms...
to acute ischemic stroke was 10.8 days. In the remaining studies, the ischemic strokes were diagnosed at the ICU. While the Dutch study did not mention whether the patients showed any focal neurological signs, in the French study, brain imaging was performed due to unexplained encephalopathy symptoms in patients without any focal neurological deficits [19].

Only the Wuhan study provided data concerning the etiology of the ischemic strokes: five of the eleven ischemic strokes were classified as macroangiopathic, three as microangiopathic, and three as cardioembolic in terms of the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification[6].

3.2.2. Other acute cerebrovascular diseases

The Chinese study also included other acute cerebrovascular manifestations [6]. Of the 221 reported patients, one had a sinus vein thrombosis (0.5%), and one had a cerebral hemorrhage (0.5%). Both patients were defined as severe cases, and the cerebrovascular event occurred after more than nine days.

3.3 KQ3: Infectious/inflammatory CNS disease relating to SARS-CoV-2; KQ3.1: Neuroinvasion of SARS-COV-2

No case of an infectious/inflammatory CNS disease associated with SARS-CoV-2 was described in the cohort studies. That is why for KQ3 we also included case studies and case series. In nine articles, the data of 15 individuals was presented [5, 23–25, 27–31, 33]. The main symptoms and diagnostic results (neurological examination, brain imaging, CSF, electroencephalography, PCR tests) are included in Table 2. In two COVID-19 patients, the CSF was positive for SARS-CoV-2 in the PCR test [26–28]. One of these was a case of meningoencephalitis associated with COVID-19 and took place in Japan [28]. A 24-year-old man was admitted to the hospital because of generalized seizures and loss of consciousness. He already had shown symptoms of a general infection several days before. Neck stiffness was detected. The MRI supported the assumption of a meningoencephalitis. The nasopharyngeal swab tested negative for SARS-CoV-2 and the CSF sample positive. Both tests repeatedly led to the same results.

General symptoms of an infection, such as headache and fever, and a new-onset seizure (not described whether generalized or focal) were also present in the case of a 41-year-old female in the USA [26, 27]. Neck stiffness and photophobia were documented at the emergency department. In the course of the disease, she developed disorientation accompanied by hallucinations. In this case, both the nasopharyngeal swab and the CSF tested positive for SARS-CoV-2. A repetition of the tests was not stated.

In both cases, the CSF results were not sufficiently presented to allow a more precise interpretation regarding an impairment of the blood–brain barrier. As for neurotropic viruses, only the herpes simplex virus and the varicella zoster virus were excluded. Additionally, in the second case, cerebral imaging was entirely missing.

In the other seven case studies and series with 13 individuals, the PCR tests for SARS-CoV-2 in the CSF samples were negative [23–25, 29–31, 33]. In total, only two studies repeated the PCR tests on the CSF samples [24, 28].

CSF testing was also carried out in the previously mentioned study of Helms et al., in which seven patients with unexplained encephalopathy symptoms were lumbar punctured. In none of these patients could SARS-CoV-2 be detected by PCR tests [19]. However, whether cerebral imaging indicated an inflammatory process or the results of the liquor samples were released in detail to prove if there is any hint of SARS-CoV-2.
Notable is a case report of Xiang et al. that described consciousness impairment in a 56-year-old male COVID-19 patient \[5\]. The CSF of the patient was also positive for SARS-CoV-2 in the PCR test, but this was not included in this review due to the publication language (Chinese).

4. Discussion

Initially, neurological manifestations were not the focus of attention in the scientific discourse of SARS-CoV-2. In the meantime, an increasing number of articles on the neurological manifestations of SARS-CoV-2 have been published, even first reviews that summarize these data \[34–36\]. While previously published reviews covered a wide range of neurological symptoms and included case reports for all outcomes, we focused on CNS disorders and prespecified a best-evidence approach. Although ours is a rapid review, it has methodological advantages such as a discriminated literature search, a risk of bias and GRADE assessment, and the inclusion of a quantitative analysis (regarding acute ischemic stroke). We consider these steps necessary to assess the available evidence.

Our meta-analysis of four cohort studies including a total of 851 patients with COVID-19 infections showed that 3.3% (95% CI: 2.2–4.9; follow-up range one to five weeks) suffered from an ischemic stroke. The Wuhan study was the only one of the included publications that provided the data of the total population and of the stroke patients separately\[6\]. A comparison of these results with an epidemiological study of patients with ischemic stroke in China (n = 19,604, median age 65 years) is limited due to the low number of cases in the Wuhan COVID-19 study. However, in the Wuhan COVID-19 study, previous cardio-cerebrovascular diseases were known in fewer patients with an acute cerebrovascular event (23.1% vs. 42.7% [atrial fibrillation and previous stroke or TIA]), and diabetes was two times more frequent than in the epidemiological study (46.2% vs. 20.7) \[6, 37\]. The percentage of patients with previous arterial hypertension was similar in both studies. In regard to age, a case series of five COVID-19 ischemic stroke patients with a lower age (ranged between 33 and 49 years) remains outstanding \[38\].

In comparison to our meta-analysis, Yaghi et al. described a lower rate of ischemic strokes in patients with COVID-19 infections in New York City with a follow-up of up to four weeks \[39\]. Referring to 3,556 hospitalized COVID-19 patients, the researchers reported 32 patients with COVID-19 that suffered from an ischemic stroke. That indicates an incidence of ischemic stroke in COVID-19 patients of 0.9%. However, they did not specify where they derived the number of 3,556 COVID-19 patients and did not state the characteristics of the total population. Furthermore, not all of the 3,556 COVID-19 patients were tested for SARS-CoV-2 with a PCR test. The fact that stroke patients without respiratory symptoms of COVID-19 may have been wrongly excluded should not be underestimated. Particularly, as we know, patients with severe cases of COVID-19 have fewer typical symptoms, such as dry cough and fever, than patients with mild cases of COVID-19. \[22\] In regard to the data provided, it is not possible to draw conclusions about the stroke incidence and, therefore, we decided against a post-hoc inclusion of this study. In contrast, in the two larger studies included in our meta-analysis, COVID-19 was laboratory proven in all patients, and the baseline characteristics of the population were described in detail \[6, 21\].

In the past, respiratory infections in general were repeatedly associated with an increased incidence of ischemic stroke \[40–43\]. In 2018, Blackburn et al. presented their results of a time-series analysis of English hospital admissions for stroke and myocardial infarction \[40\]. They reported that respiratory viruses except
parainfluenza were significantly associated with ischemic stroke admission in the elderly (≥ 75 years). In particular, influenza was widely discussed in the scientific discourse because an influenza vaccination is available and may possibly lead to a risk reduction [44]. However, the evidence is limited due to the lack of randomized controlled studies. A high concentration of C-reactive protein (CRP) was also discussed as a marker of elevated risk of ischemic stroke [45]. In the Wuhan study, the mean CRP concentration in patients with cerebrovascular events was significantly higher than in those without (51.1 mg/dl vs. 12.1 mg/dl) [6]. Nevertheless, the relevance of CRP to ischemic cerebrovascular disease remains unclear. Associations with ischemic stroke depend significantly on conventional risk factors and other laboratory signs of inflammation [45]. Of course, treatment teams must also consider laboratory signs and the general risks of hypercoagulability. Further, confounding atrial fibrillation must be taken into account because previous studies showed that new-onset atrial fibrillation occurs more frequently in the context of sepsis [46, 47]. The presence of atrial fibrillation was not explicitly stated in any of the included studies of our meta-analysis.

Genetically related coronaviruses caused SARS and MERS pandemics. During these past pandemics, virus-related neurological symptoms and acute cerebrovascular disease were rather a marginal issue. [48] The latter had been associated with the intravenous administration of immunoglobulins. Umapathi et al. reported five patients with large artery cerebral infarctions among 206 SARS patients in Singapore. Three of the five patients received intravenous immunoglobulins. The proportion of critically ill cases was 23.3%; further information on the age and comorbidities of the study population was not reported [49]. In comparison, the proportion of severe cases in the two larger COVID-19 studies was 42.7% and 17.3%, respectively [6, 21].

In SARS and MERS, there have also been isolated case reports of associated infectious/inflammatory brain diseases, of which only two showed positive PCR results in CSF analyses [12, 15, 50]. In addition, in SARS, the virus was detected in the brain tissue of an affected patient [14] and of autopsied patients [11, 13]. The current pandemic involves several isolated cases of infectious/inflammatory brain diseases associated with SARS-CoV-2, however, only two cases in which the virus was detected in the patient’s CSF [26–28]. It is generally accepted that a positive PCR result in the CSF is an indication of direct viral infection of the brain. However, one must bear in mind that during COVID-19, a marked systemic inflammatory response syndrome (SIRS) has been described [51]. In this context, the proinflammatory cytokine storm is likely to lead to an increased permeability of the blood–brain barrier [52]. The receptor by which SARS-Cov-2 enters its host cell is the angiotensin-converting enzyme 2 (ACE2) receptor. Immunohistochemistry for the ACE2 receptor in CNS tissue, though with limited description, failed to show neuronal or glial positivity but did confirm it in the brain vasculature [8]. Hence, viral replication in the brain’s microvasculature in parallel with an open blood–brain barrier could explain the CSF detection of virus particles despite the absence of neuronal/glial cell invasion. An additional receptor binding the spike protein of SARS-Cov-2 has been possibly recognized in CD147 through an in vitro experiment, and CD147 is widely present in the CNS [53]. However, taken together with the paucity of reports on meningoencephalitis associated with COVID-19, direct CNS infection seems to be rare or confined to very special patient/virus constellations during SARS-Cov-2.

In both reported cases referenced in the current review, the CSF results were not presented sufficiently to allow a more precise interpretation regarding an impairment of the blood–brain barrier, and the results of important diagnostic tests were missing (e.g., brain imaging, exclusion of further neurotropic viruses, intrathecal synthesis of antibodies) [26–28]. At least, the following must be considered: CSF tests for SARS-CoV-2 were rarely
reported, and the test accuracy of the various test kits was not specified. It is to be expected that a possible positive result can also be a false positive. That is why the data extraction of case reports included whether the CSF PCR tests were repeated. Overall, in only two case studies were the PCR tests on the CSF samples repeated [24, 28], and in one the results were SARS-CoV-2-positive twice [28].

Overall, our results support the assumptions of other reviews. Considering the results in context with those of previously published studies, the following implications can be outlined: The treatment team for patients with an infection of SARS-CoV-2, particularly with severe disease progression, should be aware of the development of neurological signs and symptoms. The integration of neurologists into the multiprofessional COVID-19 treatment team can help detect neurological complications early. Introducing a suitable risk assessment concerning hypercoagulability in severe COVID-19 cases may be particularly important, following a recent meta-analysis that revealed that acute cerebrovascular disease in COVID-19 patients was associated with an increased poor composite outcome and mortality [54].

Furthermore, in the pandemic situation, even if the symptoms are exclusively neurological, a SARS-CoV-2 infection should be considered, and patients should be tested accordingly.

Obviously, more clinical studies are needed to improve the current evidence of the neurological CNS manifestations of SARS-CoV-2. In our search we also identified ongoing studies, which can provide more detailed information, for example, on the prevalence of acute encephalopathy in severely ill COVID-19 patients or on the long-term cognitive deficits in COVID-19 patients with acute neurological symptoms [55, 56].

5. Limitations Of The Review

Due to the urgency of the COVID-19 pandemic, we conducted a rapid review and abbreviated certain methodological steps of the review process. Specifically, we applied a single risk of bias assessment, data extraction, and certainty of evidence rating, with a second person checking for plausibility and correctness.

There was a limitation in regard to language; full texts only in German and English were included. This concerned only two case studies. It has been proved in previous studies that the exclusion of non-English publications from systematic reviews had a minimal effect on the overall conclusions [57]. We are confident that none of these limitations changed the overall conclusions of this review.

However, the evidence of a review is only as solid as the underlying primary studies. Due to the low number of studies, we conducted a quantitative analysis for only one outcome (ischemic stroke). The study of Li et al. was a preprint and the manuscript was not peer-reviewed [6]. For infectious/inflammatory CNS disease associated with SARS-CoV-2, we referred to case studies, as this outcome was not described in any cohort study. Nevertheless, our numbers, especially those of the cerebrovascular events, can be used as a first orientation.

6. Conclusion

Central nervous complications occur frequently in patients with COVID-19 and are most likely of parainfectious origin. It is important to integrate neurologists into the multiprofessional COVID-19 treatment team in order to detect neurological complications early and to treat them correctly.
8. List Of Abbreviations

ACE2 receptor: angiotensin-converting enzyme 2 receptor

CNS: central nervous system

COVID-19: Coronavirus disease 2019

CSF: cerebrospinal fluid

CT: computer tomography

EEG: electroencephalography

GCS: glasgow coma scale

GRADE: Grading of Recommendations Assessment, Development and Evaluation

HSV: herpes simplex virus

ICU: intensive care unit

KQ: key question

MERS: Middle East Respiratory Syndrome

MRI: magnetic resonance imaging

NA: not available;

PCR: polymerase chain reaction

ROBINS-I: Risk Of Bias In Non-randomized Studies - of Interventions

SARS: Severe Acute Respiratory Syndrome

SARS-CoV-2: Severe Acute Respiratory Syndrome - Coronavirus 2

SD: standard deviation

SIRS: systemic inflammatory response syndrome

VZV: varicella-zoster virus

10. Declarations

10.1 Ethics approval and consent to participate

Not applicable
10.2 Consent for publication

Not applicable

10.3 Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].

10.4 Competing interests

The authors declare that they have no competing interests.

10.5 Funding

Our study was funded by the Lower Austrian Provincial Clinics Holding and is the result of a research project carried out in the evidence-based medicine information center's framework. The funding source had no role in the collection, analysis, or interpretation of the data, in the writing of the report, or in the decision to submit the article for publication.

10.6 Authors' contributions

V.M. devised the protocol for the review and coordinated the reviewing process of abstracts and full-text articles. I.K. conducted the literature search. V.M. and A.G. conducted the screening of articles, extracted the data and performed the statistical analysis. V.M., A.G., G.G. and P.L. wrote the manuscript. All authors have read and approved the manuscript. V.M. is responsible for the integrity of the work as a whole.

10.7 Acknowledgements

We wish to thank Edith Kertesz from the Danube University Krems for administrative support.

References

1. World Health Organization. Rolling updates on coronavirus diseases (COVID-19). (2020). Accessed 3. April 2020.

2. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (2020). Accessed March 26, 2020.

3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382 18:1708–20. doi:10.1056/NEJMoa2002032.

4. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease
(COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020. doi:10.1007/s00405-020-05965-1.

5. Xiang P, Xu XM, Gao LL, Wang HZ, Xiong HF, Li RHea. First case of 2019 novel coronavirus disease with Encephalitis. http://www.xinhuanet.com/english/2020-03/05/c_138846529.htm (2020). Accessed.

6. Li Y, Wang M, Zhou Y, Chang J, Xian Y, Mao L, et al. Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study. SSRN Electronic Journal. 2020. doi:10.2139/ssrn.3550025.

7. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chemical Neuroscience.

8. Toljan K. Letter to the Editor Regarding the Viewpoint "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanism". Acs Chemical Neuroscience. 2020;08:08. doi:https://dx.doi.org/10.1021/acschemneuro.0c00174.

9. Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, et al. Middle East Respiratory Syndrome. N Engl J Med. 2017;376 6:584–94. doi:10.1056/NEJMsr1408795.

10. Desforges M, Le Coupanec A, Dubeau P, Bourgoin A, Lajoie L, Dubé M, et al. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses. 2020;12(1):14-. doi:10.3390/v12010014.

11. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202 3:415–24. doi:10.1084/jem.20050828.

12. Lau KK, Yu WC, Chu CM, Lau ST, Sheng B, Yuen KY. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis. 2004;10(2):342–4. doi:10.3201/eid1002.030638.

13. Zhang QL, Ding YQ, Hou JL, He L, Huang ZX, Wang HJ, et al. [Detection of severe acute respiratory syndrome (SARS)-associated coronavirus RNA in autopsy tissues with in situ hybridization]. Di Yi Jun Yi Da Xue Xue Bao. 2003;23 11:1125–7.

14. Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, et al. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis. 2005;41 8:1089–96. doi:10.1086/444461.

15. Hung EC, Chim SS, Chan PK, Tong YK, Ng EK, Chiu RW, et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem. 2003;49 12:2108–9. doi:10.1373/clinchem.2003.025437.

16. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS med. 2009;6 7:e1000097.

17. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. bmj. 2016;355:i4919.

18. Morgan RL, Thayer KA, Bero L, Bruce N, Falck-Ytter Y, Gherai S, et al. GRADE: Assessing the quality of evidence in environmental and occupational health. Environ Int. 2016;92–93:611–6. doi:10.1016/j.envint.2016.01.004.

19. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenk M, Kummerlen C, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020. doi:10.1056/NEJMc2008597.
20. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020. doi:10.1016/j.thromres.2020.04.041.

21. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. doi:10.1016/j.thromres.2020.04.024.

22. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020;10:10. doi:https://dx.doi.org/10.1001/jamaneurol.2020.1127.

23. Bernard-Valnet R, Pizzarotti B, Anichini A, Demars Y, Russo E, Schmidhauser M, et al. Two patients with acute meningo-encephalitis concomitant to SARS-CoV-2 infection. Eur J Neurol. 2020. doi:10.1111/ene.14298.

24. Chaumont H, Etienne P, Roze E, Couratier C, Roger PM, Lannuzel A. Acute meningoencephalitis in a patient with COVID-19. Rev Neurol (Paris). 2020. doi:10.1016/j.neurol.2020.04.014.

25. Dogan L, Kaya D, Sarikaya T, Zengin R, Dincer A, Akinci IO, et al. Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: Case series. Brain Behav Immun. 2020. doi:10.1016/j.bbi.2020.05.022.

26. Duong L, Xu P, Liu A. Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles, early April 2020. Brain Behav Immun. 2020. doi:10.1016/j.bbi.2020.04.024.

27. Huang YH, Jiang D, Huang JT. SARS-CoV-2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID-19 Encephalitis. Brain Behav Immun. 2020. doi:10.1016/j.bbi.2020.05.012.

28. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first Case of Meningitis/Encephalitis associated with SARS-Coronavirus-2. International Journal of Infectious Diseases. 2020;03.03. doi:https://dx.doi.org/10.1016/j.ijid.2020.03.062.

29. Pilotto A, Odolini S, Stefano Masciocchi S, Comelli A, Volonghi I, Gazzina S, et al. Steroid-responsive encephalitis in Covid-19 disease. Ann Neurol. 2020. doi:10.1002/ana.25783.

30. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun. 2020. doi:10.1016/j.bbi.2020.04.017.

31. Yin R, Feng W, Wang T, Chen G, Wu T, Chen D, et al. Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019. J Med Virol. 2020. doi:10.1002/jmv.25888.

32. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv. 2020;2020.02.22.20026500; doi:10.1101/2020.02.22.20026500.

33. Zanin L, Saraceno G, Panciani PP, Renisi G, Signorini L, Migliorati K, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien). 2020. doi:10.1007/s00701-020-04374-x.

34. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020;413:116832. doi:10.1016/j.jns.2020.116832.

35. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg. 2020;194:105921.
36. Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: A systematic review and current update. Acta Neurol Scand. 2020. doi:10.1111/ane.13266.
37. Wangqin R, Laskowitz DT, Wang Y, Li Z, Wang Y, Liu L, et al. International Comparison of Patient Characteristics and Quality of Care for Ischemic Stroke: Analysis of the China National Stroke Registry and the American Heart Association Get With The Guidelines–Stroke Program. J Am Heart Assoc. 2018;7 20:e010623. doi:10.1161/JAHA.118.010623.
38. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med. 2020;382 20:e60. doi:10.1056/NEJMc2009787.
39. Yaghi S, Ishida K, Torres J, Mac Gory B, Raz E, Humbert K, et al. SARS2-CoV-2 and Stroke in a New York Healthcare System. Stroke. 2020:TROKEAHA120030335; doi:10.1161/STROKEAHA.120.030335.
40. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-Confirmed Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction and Stroke: Time-Series Analysis of English Data for 2004–2015. Clin Infect Dis. 2018;67 1:8–17. doi:10.1093/cid/cix1144.
41. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke. 2003;34 10:2518–32. doi:10.1161/01.STR.000009015.51603.CC.
42. Paganini-Hill A, Lozano E, Fischberg G, Perez Barreto M, Rajamani K, Ameriso SF, et al. Infection and risk of ischemic stroke: differences among stroke subtypes. Stroke. 2003;34 2:452–7. doi:10.1161/01.str.0000053451.28410.98.
43. Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018;51 3; doi:10.1183/13993003.01794-2017.
44. Lee KR, Bae JH, Hwang IC, Kim KK, Suh HS, Ko KD. Effect of Inuenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2017;48:3–4. doi:10.1159/000478017. 103 – 10.
45. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375 9709:132–40. doi:10.1016/S0140-6736(09)61717-7.
46. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial brillation. Circulation. 2003;108 24:3006–10. doi:10.1161/01.CIR.0000103131.70301.4F.
47. Kuipers S, Klein Klouwenberg PM, Cremer OL. Incidence, risk factors and outcomes of new-onset atrial brillation in patients with sepsis: a systematic review. Crit Care. 2014;18 6:688. doi:10.1186/s13054-014-0688-5.
48. Tsai LK, Hsieh ST, Chang YC. Neurological manifestations in severe acute respiratory syndrome. Acta Neurol Taiwan. 2005;14 3:113–9.
49. Umapathi T, Kor AC, Venketasubramanian N, Lim CC, Pang BC, Yeo TT, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251 10:1227–31. doi:10.1007/s00415-004-0519-8.
50. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, et al. Severe neurologic syndrome associated with Middle East respiratory syndrome coronavirus (MERS-CoV). Infection. 2015;43 4:495–501. doi:10.1007/s15010-015-0720-y.

51. Song P, Li W, Xie J, Hou Y, You C. Cytokine Storm Induced by SARS-CoV-2. Clin Chim Acta. 2020. doi:10.1016/j.cca.2020.06.017.

52. Haruwaka K, Ikegami A, Tachibana Y, Ohno N, Konishi H, Hashimoto A, et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun. 2019;10 1:5816; doi:10.1038/s41467-019-13812-z.

53. https://4356(09)00179-6/fulltext Accessed.

54. Pranata R, Huang I, Lim MA, Wahjoepramono PEJ, July J. Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 - Systematic Review, Meta-analysis, and Meta-regression. J Stroke Cerebrovasc Dis. 2020:104949; doi:10.1016/j.jstrokecerebrovasdis.2020.104949.

55. Ictal-Group. Acute Encephalopathy in Critically Ill Patients With SARS-Cov-2 Infection. In.; 2020.

56. Andersen G, Blauenfeld R: COVID-19 Prevalence and Cognitive Deficits in Neurological Patients (Neuro-Covid). In. ClinicalTrials.gov; 2020.

57. Nussbaumer-Streit B, Klerings I, Dobrescu Al, Persad E, Stevens A, Garrity C, et al. Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. J Clin Epidemiol. 2020;118:42–54. doi:10.1016/j.jclinepi.2019.10.011.

Figures
Figure 1

Figure 1
### Ischemic stroke in patients with COVID-19

| Study Name  | Event Rate | Lower Limit | Upper Limit | Total |
|-------------|------------|-------------|-------------|-------|
| Heims 2020  | 0.034      | 0.009       | 0.128       | 2 / 58|
| Klock 2020  | 0.027      | 0.011       | 0.064       | 5 / 184|
| Li 2020     | 0.050      | 0.028       | 0.088       | 11 / 221|
| Lodigiani 2020 | 0.023 | 0.012 | 0.044 | 9 / 388|

Event rate and 95% CI

Random-Effects Meta-Analysis: I²: 8.2%; Tau: 0.12

---

**Figure 2**

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- PRISMA2009checklist.doc
- Additionalfile1.docx